Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1605-1613

  Dodd, Allison Hedley ^a   Colby, Margaret S ^a   Boye, Kristina S ^b   Fahlman, Cheryl ^a   Kim, Sunny ^c   Briefel, Ronette R ^a  

^a MATHEMATICA POLICY RESEARCH   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Glucose control; HbA1c; NHANES; Prescription medication; Treatment; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; UNITED STATES; AGED; ARTICLE; BLOOD; ETHNOLOGY; FACTUAL DATABASE; METABOLISM; MIDDLE AGED; OBESITY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; UNITED STATES; YOUNG ADULT;

EID: 67650472212     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902973300     Document Type: Conference Paper

References (22)

1. Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329:977-86
2. 1c - a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003;41:1182-90
3. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
4. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA 1999;281:2005-12
5. UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53
6. UK Prospective Diabetes Study Group (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
7. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
8. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
9. American Diabetes Association (ADA). Standards of Medical Care in Diabetes - 2008. Diabetes Care 2008;31:S12-54
10. International Diabetes Federation (IDF) Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005.
11. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
12. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. Adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-7
13. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006;144: 465-74
14. Koopman RJ, Mainous AG, Diaz VA, et al. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med 2005;3:60-3
15. Berger B, Stenström G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000; 60:687-93
16. National Committee for Quality Assurance. HEDIS 2008: Healthcare Effectiveness Data and Information Set. Washington, DC: National Committee for Quality Assurance, 2007
17. U.S. Department of Health and Human Services. Overweight and obesity. In: Healthy People 2010: Understanding and Improving Health. Washington, DC: DHHS; November 2000. Available at: www.healthypeople.gov/Document/html/uih/uih-4. htm#overandobese [Last Accessed 9 November 2007]
18. World Health Organization. BMI Classification. Global Database on Body Mass Index. WHO; 2006. Available at: www.who.int/bmi/index.jsp?introPage=intro- 3.html [Last Accessed 9 November 2007].
19. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy People Statistical Notes, no. 20. Hyattsville, MD: National Center for Health Statistics, January 2001
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 1995;57:289-300
21. Skyler JS. Insulin therapy in type II diabetes: who needs it, how much of it, and for how long? Postgrad Med 1997;101:85-90, 92-4, 96
22. American Diabetes Association (ADA). Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20